ENHERTU 100 MG

The defining feature of Trastuzumab deruxtecan is its her2 antibody-drug conjugate with topoisomerase i inhibitor payload activity. HER2 antibody delivers a cleavable topoisomerase I inhibitor payload, causing DNA damage and a bystander effect. HER2 biology is central to treatment selection, and the clinical role depends on the tumor's HER2 status and disease setting. Within this database it is listed under Targeted Therapy; Antibody-Drug Conjugate; HER2-Directed Therapy. The principal indications are HER2-positive breast cancer; HER2-low/ultralow breast cancer in selected settings; HER2-positive gastric/GEJ cancer; HER2-mutant NSCLC and other HER2-positive solid tumors in label-specific settings, with Breast; Gastric/GEJ; NSCLC; other HER2-positive solid tumors identified as the associated tumor types. Its treatment role can differ substantially between these settings, so the disease context matters as much as the drug class. Regimens listed for the medicine include T-DXd monotherapy; selected combinations under disease-specific labels. Molecular and disease-specific eligibility can therefore be more important than tumor location alone when the treatment is considered. Where a molecular alteration, receptor status, or prior-treatment requirement appears in the indication, that criterion is part of the clinical context rather than an optional detail. The medicine may consequently occupy an induction, maintenance, adjuvant, metastatic, salvage, or supportive position depending on the setting recorded here. Current product information and disease-specific guidance should be checked before clinical application.